Literature DB >> 15193399

Modulation of immune responses with transcutaneously deliverable adjuvants.

Charalambos D Partidos1, Anne-Sophie Beignon, Jean-Paul Briand, Sylviane Muller.   

Abstract

Transcutaneous immunisation is a novel vaccination strategy based on the application of antigen together with an adjuvant onto hydrated bare skin. This simple and non-invasive immunisation procedure elicits systemic and mucosal immune responses and therefore, it provides a viable and cost-effective strategy for disease prevention. For the induction of antigen-specific immune responses the use of adjuvants is critical. They potentiate and modulate the type of immune responses by stimulating the production of cytokines that drive the differentiation of T cells towards the Th1 or Th2-phenotype. These cells mediate protection against different infectious diseases and therefore, their selective induction is important for successful vaccination. In this review we give a brief overview of transcutaneously deliverable adjuvants and we discuss how they modulate immune responses to topically applied antigens.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193399     DOI: 10.1016/j.vaccine.2003.11.063

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  8 in total

1.  Cholera toxin activates nonconventional adjuvant pathways that induce protective CD8 T-cell responses after epicutaneous vaccination.

Authors:  Irlanda Olvera-Gomez; Sara E Hamilton; Zhengguo Xiao; Carla P Guimaraes; Hidde L Ploegh; Kristin A Hogquist; Liangchun Wang; Stephen C Jameson
Journal:  Proc Natl Acad Sci U S A       Date:  2012-01-23       Impact factor: 11.205

2.  Epicutaneous immunization converts subsequent and established antigen-specific T helper type 1 (Th1) to Th2-type responses.

Authors:  Jessica Strid; Robin Callard; Stephan Strobel
Journal:  Immunology       Date:  2006-06-08       Impact factor: 7.397

Review 3.  Topical vaccination: the skin as a unique portal to adaptive immune responses.

Authors:  Chun-Ming Huang
Journal:  Semin Immunopathol       Date:  2007-04       Impact factor: 9.623

4.  Transcutaneous immunization with cross-reacting material CRM(197) of diphtheria toxin boosts functional antibody levels in mice primed parenterally with adsorbed diphtheria toxoid vaccine.

Authors:  Paul Stickings; Marisa Peyre; Laura Coombes; Sylviane Muller; Rino Rappuoli; Giuseppe Del Giudice; Charalambos D Partidos; Dorothea Sesardic
Journal:  Infect Immun       Date:  2008-01-28       Impact factor: 3.441

5.  Intranasal immunization with influenza antigens conjugated with cholera toxin subunit B stimulates broad spectrum immunity against influenza viruses.

Authors:  Junwei Li; Maria T Arévalo; Yanping Chen; Olivia Posadas; Jacob A Smith; Mingtao Zeng
Journal:  Hum Vaccin Immunother       Date:  2014-03-14       Impact factor: 3.452

6.  Effect of skin barrier disruption on immune responses to topically applied cross-reacting material, CRM(197), of diphtheria toxin.

Authors:  S Godefroy; M Peyre; N Garcia; S Muller; D Sesardic; C D Partidos
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

7.  Regulatory T cells and IL-10 independently counterregulate cytotoxic T lymphocyte responses induced by transcutaneous immunization.

Authors:  Pamela Stein; Michael Weber; Steve Prüfer; Beate Schmid; Edgar Schmitt; Hans-Christian Probst; Ari Waisman; Peter Langguth; Hansjörg Schild; Markus P Radsak
Journal:  PLoS One       Date:  2011-11-16       Impact factor: 3.240

8.  Epicutaneous immunization with type II collagen inhibits both onset and progression of chronic collagen-induced arthritis.

Authors:  Jessica Strid; Lee Aun Tan; Stephan Strobel; Marco Londei; Robin Callard
Journal:  PLoS One       Date:  2007-04-18       Impact factor: 3.240

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.